Want to see NERV full AI Analyst Report?
Minerva Neurosciences (NERV) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Risperidone, Olanzapine, Aripiprazole, Roluperidone, Min-101 | Negative Symptoms Of Schizophrenia | Phase III | Recruiting | Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications | Apr 21, 2026 | ― |
| Roluperidone 64 Mg, Olanzapine 10 Mg | Negative Symptoms In Schizophrenia | Phase I | Completed | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia | Oct 13, 2023 | ― |
| Min-117 5.0 Mg, Min-117 2.5 Mg | Major Depressive Disorder | Phase II | Completed | A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder | Feb 20, 2018 | ― |
| Roluperidone 32 Mg, Roluperidone 64 Mg | Negative Symptoms Of Schizophrenia | Phase III | Completed | Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia | Dec 29, 2017 | ― |
| Min-101 | Healthy Subjects | Phase I | Completed | A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers | Feb 23, 2017 | ― |
| Min-101 | Healthy Subjects | Phase I | Completed | A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects | Jan 10, 2017 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Risperidone, Olanzapine, Aripiprazole, Roluperidone, Min-101 | Phase III | Negative Symptoms Of Schizophrenia | Recruiting | Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications | Apr 21, 2026 | ― |
| Roluperidone 64 Mg, Olanzapine 10 Mg | Phase I | Negative Symptoms In Schizophrenia | Completed | A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia | Oct 13, 2023 | ― |
| Min-117 5.0 Mg, Min-117 2.5 Mg | Phase II | Major Depressive Disorder | Completed | A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder | Feb 20, 2018 | ― |
| Roluperidone 32 Mg, Roluperidone 64 Mg | Phase III | Negative Symptoms Of Schizophrenia | Completed | Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia | Dec 29, 2017 | ― |
| Min-101 | Phase I | Healthy Subjects | Completed | A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers | Feb 23, 2017 | ― |
| Min-101 | Phase I | Healthy Subjects | Completed | A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects | Jan 10, 2017 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Minerva Neurosciences (NERV) have in its pipeline
Minerva Neurosciences NERV is currently developing the following drugs: Risperidone, Olanzapine, Aripiprazole, Roluperidone, Min-101, Roluperidone 64 Mg, Olanzapine 10 Mg, Min-117 5.0 Mg, Min-117 2.5 Mg, Roluperidone 32 Mg, Roluperidone 64 Mg, Min-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
